KhannaR.Dialysis considerations for diabetic patients.Kidney Int1993; 43(Suppl 40): S58–64.
2.
ScarpioniL., BallocchiS., CastelliA., ScarpioniR.Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis: Comparison of intraperitoneal and subcutaneous administration.Perit Dial Int1994; 14: 127–31.
3.
NevalainenP., LahtelaJ.T., MustonenJ., PasternackA.The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type I diabetic patients.Nephrol Dial Transplant1997; 12: 145–50.
4.
FeligP., WahrenJ.The liver as site of insulin and glucagon action in normal, diabetic and obese humans.Isr J Med Sci1975; 11: 528.
5.
DuckworthW.C.Insulin degradation: Mechanisms, products and significance.Endocr Rev1988; 9: 319–45.
6.
DuckworthW.C., SaudekC.D., HenryR.R.Why intra peritoneal delivery of insulin with implantable pump in NIDDM?Diabetes1992; 41: 657–61.
7.
FullerJ.H., ShipleyM.J., RoseG., JarrettR.J., HeenH.Coronary heart disease risk and impaired glucose tolerance: The White Hall study.Lancet1983; i: 1373–6.
8.
PyoralaK.Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland.Diabetes Care1979; 2: 131–41.
9.
RubinJ., ReedV., AdairC., BowerJ., KleinE.Effect of intraperitoneal insulin on solute kinetics in CAPD: Insulin kinetics in CAPD (Abstract).Am J Med Sci1986; 291: 81.
MicossiP., CrostalloM., LibrentiM.C., PetrellaG., GalimbertiG., MelandriM.Free-insulin profiles after intraperitoneal, intramuscular and subcutaneous insulin administration.Diabetes Care1986; 9: 575–8.
12.
ScalamognaA., CastelnovaC., CrepaldiM., GuerraL., GrazianiG., CantaluppiA.Incidence of peritonitis in diabetic patients on CAPD: Intraperitoneal vs subcutaneous insulin therapy. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in continuous ambulatory peritoneal dialysis.Toronto: University of Toronto Press, 1987; 3: 166–70.
13.
Diaz-BuxoJ.A.Automated peritoneal dialysis. In: JacobsC., KjellstrandC.M., KochK.M., WinchesterJ.F., eds. Replacement of renal function by dialysis.4th ed.Dordrecht: Kluwer Academic, 1996: 546–61.
14.
ViglinoG., CancariniG.C., CatizoneL., CocchiR., De VecchiA., LupoA.Ten years experience of CAPD in diabetics: Comparison of results with non-diabetics.Nephrol Dial Transplant1994; 9: 1443–8.
15.
SelgasR., Lopez-RivasA., AlvaroF., TarduchyG.R., RuedaP., MuñozJ.Insulin influence on the mitogenic-induced effect of the peritoneal effluent in CAPD patients. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1989; 5: 161–4.
16.
WanlessI.R., BargmanJ.M., OreopoulosD.G., VasS.I.Sub-capsular steatosis in response to peritoneal insulin delivery: A clue to the pathogenesis of steatonecrosis in obesity.Mod Pathol1989; 2: 69–74.
17.
TzamaloukasA.H., OreopoulosD.G.Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: A review. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1991; 7: 81–5.
18.
HarrisonN.A., RainfordD.J.Intraperitoneal insulin and the malignant omentum syndrome (Abstract).Nephrol Dial Transplant1988; 3: 103.
19.
Diaz-BuxoJ.A.Blood glucose control in diabetics: I.Semin Dial1993; 6: 392–3.
20.
DanielsI.D., MarkellM.S.Blood glucose control in diabetics: II.Semin Dial1993; 6: 394–7.
21.
MaxwellD.R., PrinceM.J.Blood glucose control in diabetics: III.Semin Dial1993; 6: 397–9.
22.
Canada-USA (CANUSA) Peritoneal Dialysis Study Group.Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical out comes.J Am Soc Nephrol1996; 7: 198–207.
23.
TeehanB.P., SchleiferC.R., BrownJ.Urea kinetic modeling is an appropriate assessment of adequacy.Semin Dial1992; 5: 189–92.
24.
LowrieE.G., HuangW.H., LewN.L.Death risk predictors among peritoneal dialysis and hemodialysis patients: A preliminary comparison.Am J Kidney Dis1995; 26: 220–8.
25.
DaviesS.J., RussellL., BryanJ., PhillipsL., RussellG.I.Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: Their interrelationship and prediction of survival.Am J Kidney Dis1995; 26: 353–61.
26.
MaiorcaR., BrunoriG., ZubaniR., CancariniG.C., ManiliL., CameriniC.Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study.Nephrol Dial Transplant1995; 10: 2295–305.
27.
AvramM.M., GoldwasserP., ErroaM., FeinP.A.Predictors of survival in continuous ambulatory peritoneal dialysis patients: The importance of prealbumin and other nutritional and metabolic markers.Am J Kidney Dis1994; 23: 91–8.
28.
ChertowG.M., LingJ., LewN.L., LazarusJ.M., LowrieE.G.The association of intradialytic parenteral nutrition administration with survival in hemodialysis patients.Am J Kidney Dis1994; 24: 912–20.
29.
ChertowG.M., LazarusJ.M., LydenM.E.Laboratory surrogates of nutritional status after administration of intraperitoneal amino acid-based solutions in ambulatory peritoneal dialysis patients.J Renal Nutr1995; 5: 116–23.
McTavishD., GoaK.L.Midodrine: A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders.Drugs1989; 38: 757–77.
33.
ZachariahP.K., BloedowD.C., MoyerT.P., ShepsS.G., SchirgerA., FealeyR.D.Pharmacodynamics of midodrine, an antihypertensive agent.Clin Pharmacol Ther1986; 39: 586–91.
34.
ThulesiusO., GjoresJ.E., BerlinE.Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine, and dihydroergotamine on isolated human veins.Eur J Clin Pharmacol1979; 16: 423–4.
35.
LowP.A., GildenJ.L., FreemanR., ShengK., McElligottM.A., for the Midodrine Study Group. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: A randomized, double-blind multicenter study.JAMA1997; 277: 1046–51.
36.
HamburgerR.J., ChristP.G., MorrisP.A., LuftF.C.Hypertension in dialysis patients: Does CAPD provide an advantage? In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1989; 5: 91–6.
37.
RamosJ.M., GokalR., SiamopolousK., WardM.K., WilkinsonR., KerrD.N.S.Continuous ambulatory peritoneal dialysis: Three years experience.Q J Med1983; 206: 165–86.
38.
YoungM.A., NolphK.D., DultonS., ProwantB.F.Anti- hypertensive drug requirements in continuous ambulatory peritoneal dialysis.Perit Dial Bull1984; 4: 85–8.
VelasquezM.T., LewS.Q., Von AlbertiniB., MishkinG.J., BoschJ.P.Control of hypertension is better during hemodialysis than during continuous ambulatory peritoneal dialysis in ESRD patients.Clin Nephrol1997; 48: 341–5.
41.
BlakeP.G., FlowerdewG., BlakeR.M., OreopoulosD.G.Serum albumin in patients on continuous ambulatory peritoneal dialysis -predictors and correlations with outcomes.J Am Soc Nephrol1993; 3: 1501–7.
42.
NolphK.D., MooreH.L., ProwantB.F., TwardowskiZ.J., KhannaR., GamboaS.Continuous ambulatory peritoneal dialysis with a high flux membrane.ASAIO J1993; 39: 904–9.
43.
MalhotraD., TzamaloukasA.H., MurataG.H., FoxL., GoldmanR.S., AvasthiP.S.Serum albumin in continuous peritoneal dialysis: Its predictors and relationship to urea clearance.Kidney Int1996; 50: 243–9.
44.
BlakeP.G.What is the problem with high transport ers?Perit Dial Int1997; 17: 317–20.
45.
ChurchillD.N., ThorpeK.E., NolphK.D., KeshaviahP.R., PageD., Oreopoulos DG, for the Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Increased peritoneal membrane transport is associated with decreased CAPD technique and patient survival (Abstract).J Am Soc Nephrol1997; 8: 189A.
46.
ChurchillD.N., ThorpeK.E., NolphK.D., OreopoulosD.G., PageD., Keshaviah PR, for the Canada-USA (CANUSA) Peritoneal Dialysis Study Group. CAPD patient and technique survivals are worse with increased membrane permeability (Abstract).Perit Dial Int1996; 16(Suppl 2): S21.
SelgasR., BajoM.A., Fernandez-ReyesM.J., BosqueE., Lopez-RevueltaK., JimenezC.An analysis of adequacy of dialysis in a selected population on CAPD for over 3 years: The influence of urea and creatinine kinetics.Nephrol Dial Transplant1993; 8: 1244–53.
49.
LalS.M., MooreH.L., NolphK.D.Effects of intraperitoneal captopril on peritoneal transport in rats.Perit Dial Bull1987; 7: 80.
